Drug Classification:

Artemether + Lumefantrine is classified as an antimalarial agent. It combines two active ingredients, Artemether and Lumefantrine, which work synergistically to eradicate malaria parasites from the body.

Formulations:

• Artemether + Lumefantrine Dry Suspension:
  • Strength: Each 5ml of suspension contains 30 mg Artemether and 180 mg Lumefantrine.
  • Product Form: Dry suspension for oral administration.
  • Packing Specifications: Supplied in a bottle containing 60ml of suspension.
• Artemether + Lumefantrine Tablets:
  • Strengths:
    • 20 mg Artemether + 120 mg Lumefantrine tablets (16’s)
    • 40 mg Artemether + 240 mg Lumefantrine tablets (8’s)
    • 80mg Artemether + 480mg Lumefantrine tablets (4’s)
  • Product Form: Oral tablets for convenient dosing.
  • Packing Specifications: Packaged in blister packs containing the specified number of tablets.

Indications:

Artemether + Lumefantrine is indicated for the treatment of uncomplicated malaria caused by Plasmodium falciparum, including multi-drug resistant strains. It is not recommended for prophylaxis or treatment of severe malaria.

Usage:

• The oral suspension should be reconstituted according to the instructions provided before administration.
• Tablets should be swallowed whole with water and may be taken with or without food.
• Patients should complete the full course of treatment as prescribed by their healthcare provider, even if symptoms improve before completion.

Dosage:

• Dosage regimens may vary based on factors such as the patient’s age, weight, and severity of infection.
• The recommended dosage for Artemether + Lumefantrine is typically based on body weight and administered twice daily for three days.
• The specific dosage for each strength of tablet or suspension should be determined by a qualified healthcare professional.

Pharmacokinetics:

• Artemether is rapidly metabolized to its active metabolite dihydroartemisinin, which has a rapid onset of action against malaria parasites.
• Lumefantrine is absorbed slowly and metabolized in the liver to its active metabolite desbutyl-lumefantrine, which contributes to the prolonged antimalarial activity.

Pharmacodynamics:

• Artemether acts rapidly to kill malaria parasites, particularly the early stages of the parasite’s life cycle, including the ring and trophozoite stages.
• Lumefantrine has a longer half-life and provides sustained antimalarial activity, preventing recrudescence of the infection and reducing the risk of treatment failure.

Side Effects:

• Common side effects of Artemether + Lumefantrine may include nausea, vomiting, diarrhea, abdominal pain, and headache.
• Rare but serious side effects may include cardiac arrhythmias, hypersensitivity reactions, and hepatic dysfunction.
• Patients should be monitored for any adverse reactions during treatment, and healthcare providers should be informed of any concerning symptoms.

Experience the efficacy and reliability of AIT Pharmaceuticals Division’s Artemether + Lumefantrine Range in the fight against malaria. For more information, please contact us. We are dedicated to advancing global health through innovative pharmaceutical solutions.